No connection

Search Results

AXSM vs MASI

AXSM
Axsome Therapeutics, Inc.
BEARISH
Price
$185.96
Market Cap
$9.37B
Sector
Healthcare
AI Confidence
68%
MASI
Masimo Corporation
BEARISH
Price
$178.47
Market Cap
$9.35B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AXSM
--
MASI
46.6
Forward P/E
AXSM
423.03
MASI
27.04
P/B Ratio
AXSM
126.85
MASI
12.89
P/S Ratio
AXSM
16.7
MASI
6.12
EV/EBITDA
AXSM
-49.31
MASI
28.16

Profitability

Gross Margin
AXSM
91.86%
MASI
61.8%
Operating Margin
AXSM
-19.25%
MASI
18.52%
Profit Margin
AXSM
-40.89%
MASI
-9.92%
ROE
AXSM
-275.5%
MASI
23.43%
ROA
AXSM
-19.79%
MASI
8.86%

Growth

Revenue Growth
AXSM
63.2%
MASI
12.0%
Earnings Growth
AXSM
--
MASI
--

Financial Health

Debt/Equity
AXSM
2.96
MASI
0.78
Current Ratio
AXSM
1.57
MASI
2.49
Quick Ratio
AXSM
1.45
MASI
1.29

Dividends

Dividend Yield
AXSM
--
MASI
--
Payout Ratio
AXSM
0.0%
MASI
0.0%

AI Verdict

AXSM BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.

Strengths
Exceptional year-over-year revenue growth of 63.20%, significantly above sector average of 39.78%
High gross margin of 91.86%, indicating strong pricing power and low cost of goods sold
Analyst consensus is strong_buy with a target price of $210.19, implying 13% upside
Risks
Piotroski F-Score of 3/9 indicates weak financial health and poor profitability trends
Extremely high forward P/E of 423x with no Graham Number, suggesting severe overvaluation relative to earnings
Negative ROE of -275.50% and negative operating margins signal deep profitability issues
MASI BEARISH

MASI exhibits a severe valuation disconnect, trading at $178.47 despite a Graham Number of $34.54 and an Intrinsic Value of $26.81. While the Piotroski F-Score of 4/9 indicates stable financial health, the company is struggling with a negative profit margin (-9.92%) and a concerning Q/Q revenue collapse of -31.33%. Strong gross margins and ROE are offset by a significant YoY EPS decline of -31.7% and bearish insider sentiment. The stock is currently priced for perfection in a deteriorating short-term growth environment.

Strengths
Strong Gross Margin (61.80%) indicating high product value
Robust Return on Equity (ROE) of 23.43%
Healthy liquidity with a Current Ratio of 2.49
Risks
Extreme overvaluation relative to Graham and Intrinsic value models
Sharp Q/Q revenue contraction (-31.33%)
Significant YoY earnings decline (-31.7%)

Compare Another Pair

AXSM vs MASI: Head-to-Head Comparison

This page compares Axsome Therapeutics, Inc. (AXSM) and Masimo Corporation (MASI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile